Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

Thomas R. Collins  |  Issue: July 2015  |  July 14, 2015

Over the past several years, not many new pharmacological interventions have been introduced. Duloxetine has been shown in trials to improve pain and function significantly compared to placebo, and is a good option for some patients, Dr. Shakoor said.

“I find duloxetine very useful in my patient population,” she said. “I’ve had some really great success with it. It’s a great option for patients who may have OA plus fibromyalgia or spinal stenosis and neuropathy and a great addition to other agents we might be using to treat their pain.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Topical nonsteroidal antiinflammatory drugs (NSAIDs) have also come into use, demonstrating less than 5% of the concentration in plasma of that seen in oral NSAIDs. They might be a good option for patients for whom physicians are reluctant to prescribe long-term oral NSAIDs.

When a drug inhibits the Jak/STAT pathway, multiple cytokines are being inhibited, & the clinical upshot of that scope of inhibition is not yet known.

But Dr. Shakoor emphasized the importance of nonpharmacological interventions as well—not just physical therapy, but also exercise and weight management. She has studied the biomechanics of the knee joint extensively and suggested that interventions lessening the load on the knee joint could help delay disease progression.

Some movement and force on the joint are necessary for nutrients to be distributed, but too much force can lead to degeneration and damage.

“We believe it’s these forces when you’re moving every day and ambulating that are really important in terms of OA process and degeneration,” Dr. Shakoor said.

The “peak external knee adduction moment,” measured through gait analysis, is a primary predictor of load over the medial compartment of the knee and is associated with OA severity progression.

“[Because] this is associated with OA progression, if we can actually lower this load, we may be able to delay progression of osteo­arthritis,” Dr. Shakoor said. She added that this is not yet proven, but is the main motivation behind her study in this area.

A brace—the valgus/unloading knee brace—can be one way to lessen these loads, although many patients find it too bulky and cumbersome.

Studies have found that bulky shoes that insulate the foot put more load on the knee joint, likely because they insulate the foot from the footfalls and because there is less use of the body’s natural reflexes to lessen hard impact.

Her lab has found that a flatter, lightweight shoe called a “mobility shoe”—with cuts in the sole to mimic the natural bends of the bare foot—brought about a 17% reduction in knee joint loads in six months compared with subjects’ usual shoes. A similar lightweight shoe is being studied in Italy and elsewhere.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesEducation & TrainingMeeting ReportsProfessional TopicsResearch RheumSystemic Lupus Erythematosus Tagged with:AC&Rclinical symposiumJAK inhibitorLupusOsteoarthritisoutcomepatient careResearchTreatment

Related Articles

    How Footwear Affects Patients with Medial Knee Osteoarthritis

    May 18, 2018

    A patient’s gait, or how they walk, is an important predictor of the biomechanical load distribution that affects osteoarthritis (OA). This understanding comes from a growing body of literature in bio­mechanics to test and treat patients with OA, which takes into account a very practical treatment: a patient’s shoes. A focus on flexible footwear, along…

    Walk This Way: How Footwear Affects Patients with Medial Knee OA

    April 26, 2018

    Studying the way patients with knee osteoarthritis walk and changes to footwear are helping patients under the care of Najia Shakoor, MD, and colleagues take control of their pain and possibly delay disease progression…

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences